Aprea Therapeutics APRE

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.15 (-6.05%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aprea Therapeutics (APRE)
    Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.33

    • Market Cap

      $12.66 Million

    • Price-Earnings Ratio

      -0.83

    • Total Outstanding Shares

      5.44 Million Shares

    • Total Employees

      7

    • Dividend

      No dividend

    • IPO Date

      October 3, 2019

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      3805 old easton road, Doylestown, PA, 18902

    • Homepage

      https://www.aprea.com

    Historical Stock Splits

    If you bought 10,000,000 shares of APRE before September 13, 2011, you'd have 1 share today.
    Execution DateSplit Amount
    February 13, 20231-for-20 (Reverse Split)
    December 27, 20181-for-1000 (Reverse Split)
    September 13, 20111-for-500 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Investing Activities, Continuing$-22,628
    Net Cash Flow, Continuing$879,390
    Net Cash Flow From Investing Activities$-22,628
    Net Cash Flow From Operating Activities, Continuing$-13.79 Million
    Net Cash Flow From Operating Activities$-13.79 Million
    Net Cash Flow From Financing Activities, Continuing$14.69 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Income/Loss Available To Common Stockholders, Basic$-13.51 Million
    Net Income/Loss$-13.51 Million
    Income/Loss From Continuing Operations Before Tax$-13.51 Million
    Operating Income/Loss$-14.77 Million
    Basic Earnings Per Share$-2.80
    Diluted Earnings Per Share$-2.80

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$-3.74 Million
    Comprehensive Income/Loss Attributable To Parent$-13.48 Million
    Comprehensive Income/Loss$-13.46 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Current Liabilities$1.81 Million
    Liabilities$4.95 Million
    Assets$26.89 Million
    Equity Attributable To Noncontrolling Interest$0
    Current Liabilities$3.64 Million
    Accounts Payable$1.15 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about APRE from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.